Clinical Trial

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2022-03-23; most recent amendment 2026-04-14.
Status change: Not Yet Recruiting → Recruiting 2022-04-05
Trial Details
NCT Number NCT05294731
Lead Sponsor BeiGene
Conditions B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia, Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Unclassifiable +1 more
Enrollment 146 participants
Start Date 2022-05-06
Primary Completion 2029-01-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-17